Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)

被引：15
|
作者：
Kenealy, Melita [1 ,2 ,3 ]
Patton, Nigel [4 ]
Filshie, Robin [5 ]
Nicol, Andrew [6 ]
Ho, Shir-Jing [7 ]
Hertzberg, Mark [8 ,9 ]
Mills, Tony [10 ]
Prosser, Ian [11 ]
Link, Emma [2 ]
Cowan, Linda [2 ]
Zannino, Diana [12 ]
Seymour, John F. [2 ,3 ]
机构：
[1] Cabrini Hlth, Dept Haematol, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Dept Haematol, Melbourne, Vic, Australia
[3] Univ Melbourne, Melbourne, Vic, Australia
[4] Royal Adelaide Hosp, Adelaide, SA, Australia
[5] St Vincents Hosp Melbourne, Melbourne, Vic, Australia
[6] Greenslopes Private Hosp, Brisbane, Qld, Australia
[7] St George Hosp, Sydney, NSW, Australia
[8] Prince Wales Hosp, Dept Haematol, Sydney, NSW, Australia
[9] Univ New South Wales, Sydney, NSW, Australia
[10] Princess Alexandra Hosp, Brisbane, Qld, Australia
[11] Canberra Hosp, Canberra, ACT, Australia
[12] Australasian Leukaemia & Lymphoma Grp, Melbourne, Vic, Australia
来源：
LEUKEMIA & LYMPHOMA | 2017年 / 58卷 / 02期
关键词：
Azacitidine; clinical trial; myelodysplastic syndrome (MDS<bold>)</bold>; thalidomide; SCORING SYSTEM; GROUP-B; CANCER;
D O I：
10.1080/10428194.2016.1190971
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Single agent azacitidine or immunomodulatory drugs are effective in myelodysplastic syndrome (MDS), with differing target mechanisms and toxicities. Objectives of this ALLG MDS3 study in clinically advanced MDS, AMML and low blast AML were to establish safety, response and quality of life of azacitidine and thalidomide. Patients received azacitidine (75mg/m(2)/d sc 7days every 28 days), and oral thalidomide up to 100mg/d for maximum 12months. Eighty patients registered; median age 68 years (range 42-82), 49% IPSS int2-high. With 36.5 months follow up, patients received median 9 cycles azacitidine, 6.1mths thalidomide. Nonhematologic toxicity grade 3+ in 85%, commonly infections. Overall response rate was 63%; 26% CR were unaffected by IPSS. Median response duration 26.3months; overall survival was 28.1months. This combination azacitidine and thalidomide in clinically advanced MDS, CMML and low-blast AML was tolerable without unexpected toxicity and encouraging responses support further investigation of combination approaches with hypomethylating agent and immunomodulatory drug.
引用
收藏
页码：298 / 307
页数：10
相关论文
共 50 条
  • [1] Results of 5-azacitidine therapy in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)
    Freyrie, A.
    Reda, G.
    Vincenti, D.
    Ferla, V.
    Orofino, N.
    Sciume, M.
    Guidotti, F.
    Cortelezzi, A.
    LEUKEMIA RESEARCH, 2013, 37 : S157 - S158
  • [2] Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
    Walker, Alison R.
    Bergua Burgues, Juan Miguel
    Montesinos, Pau
    Bixby, Dale
    Guastad Daver, Naval
    Konopleva, Marina
    Patrick Anthony, Stephen
    Tan, Fenlai
    Chen, Yi
    Chen, Yu
    Shen, Yue
    William Burke, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] EXTENDED CC-486 (ORAL AZACITIDINE) DOSING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), ACUTE MYELOID LEUKEMIA (AML), OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): SAFETY, TOLERABILITY, AND RESPONSE
    Savona, M. R.
    Kolibaba, K.
    Conkling, P.
    Kingsley, E. C.
    Becerra, C.
    Morris, J. C.
    Rifkin, R. M.
    Laille, E.
    Kellerman, A.
    Ukrainskyj, S. M.
    Dong, Q.
    Skikne, B. S.
    LEUKEMIA RESEARCH, 2015, 39 : S29 - S30
  • [4] Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
    Garcia-Manero, Guillermo
    Gore, Steven D.
    Cogle, Christopher
    Ward, Renee
    Shi, Tao
    MacBeth, Kyle J.
    Laille, Eric
    Giordano, Heidi
    Sakoian, Sarah
    Jabbour, Elias
    Kantarjian, Hagop
    Skikne, Barry
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : 2521 - 2527
  • [5] Phase II study of pevonedistat (P) plus azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777).
    Ades, Lionel
    Watts, Justin M.
    Radinoff, Atanas
    Arnan, Montserrat
    Cerrano, Marco
    Font Lopez, Patricia
    Zeidner, Joshua F.
    Diez-Campelo, Maria
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolay
    Fram, Robert J.
    Zhao, Dan
    Faller, Douglas, V
    Sekeres, Mikkael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)
    Steensma, David P.
    Wermke, Martin
    Klimek, Virginia M.
    Greenberg, Peter L.
    Font, Patricia
    Komrokji, Rami S.
    Yang, Jay
    Brunner, Andrew M.
    Carraway, Hetty E.
    Ades, Lionel
    Al-Kali, Aref
    Dominguez, Juan Manuel Alonso
    Alonso, Ana
    Coombs, Catherine C.
    Deeg, H. Joachim
    Donnellan, William B.
    Foran, James M.
    Garcia-Manero, Guillermo
    Maris, Michael B.
    McMasters, Malgorzata
    Micol, Jean-Baptiste
    De Oteyza, Jaime Perez
    Thol, Felicitas
    Wang, Eunice S.
    Watts, Justin M.
    Buonamici, Silvia
    Kim, Amy
    Gourineni, Vikram
    Marino, Alyssa J.
    Rioux, Nathalie
    Schindler, Joanne
    Smith, Sherri
    Yao, Huilan
    Yuan, Xiaobin
    Yu, Kun
    Platzbecker, Uwe
    BLOOD, 2019, 134
  • [7] A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML)
    Navada, S. C.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Alvarado, Y.
    Daver, N.
    DiNardo, C.
    Konopleva, M.
    Borthakur, G.
    Azarnia, N.
    Silverman, L. R.
    LEUKEMIA RESEARCH, 2015, 39 : S45 - S45
  • [8] Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia
    Meers, S.
    Selleslag, D.
    Potier, H.
    Glasmacher, A.
    Mineur, P.
    Voelter, V.
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (01) : 35 - 42
  • [9] IMPACT OF BONE MARROW FIBROSIS IN RESPONSE TO AZACITIDINE IN 94 PATIENTS WITH MYELODISPLASTIC SYNDROMES (MDS), CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ACUTE MYELOID LEUKEMIA
    Reda, G.
    Riva, M.
    Cassin, R.
    Fattizzo, B.
    Deodato, M.
    Freyrie, A.
    Molteni, A.
    Cairoli, R.
    Cortelezzi, A.
    HAEMATOLOGICA, 2016, 101 : 241 - 242
  • [10] Phase 2 study of pevonedistat (P) plus azacitidine (A) versus azacitidine in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (LB-AML) (NCT02610777)
    Giagounidis, A.
    Ades, L.
    Watts, J.
    Radinoff, A.
    Arnan Sangerman, M.
    Cerrano, M.
    Font Lopez, P.
    Zeidner, J.
    Diez Campelo, M.
    Graux, C.
    Liesveld, J.
    Selleslag, D.
    Tzvetkov, N.
    Fram, R. J.
    Zhao, D.
    Bell, J.
    Friedlander, S.
    Faller, D. V.
    Sekeres, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 171 - 171
12345